RYTM · ISSUER CIK 1649904
RHYTHM PHARMACEUTICALS, INC.
Between Aug 1, 2026 and Oct 29, 2026, 6 RHYTHM PHARMACEUTICALS, INC. insiders reported $0.00 of open-market purchases and $28.8M of sales on SEC Form 4.
↗6 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 6 of 6 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$28.8MInsider selling
−$28.8MNet open-market
Sep 14, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 14, 202619:37 | Sep 14, 2026 | RYTM | President and CEO, Director | S · Sell10b5-1 | $102.67 | −50,000 | 239,258 | -17% | −$5.1M | ||
| Sep 14, 202619:37 | Sep 14, 2026 | RYTM | President and CEO, Director | M · Exercise10b5-1 | $6.05 | +50,000 | 289,258 | +21% | $303K | ||
| Sep 1, 202616:22 | Aug 31, 2026 | RYTM | Chief Financial Officer | S · Sell10b5-1 | $105.46 | −62,774 | 114,024 | -36% | −$6.6M | ||
| Sep 1, 202616:22 | Aug 31, 2026 | RYTM | Chief Financial Officer | M · Exercise10b5-1 | $25.79 | +57,187 | 176,798 | +48% | $1.5M | ||
| Aug 17, 202618:00 | Aug 13, 2026 | RYTM | Chief Technical Officer | S · Sell10b5-1 | $119.75 | −5,079 | 15,915 | -24% | −$608K | ||
| Aug 17, 202618:00 | Aug 13, 2026 | RYTM | Chief Technical Officer | M · Exercise10b5-1 | $6.80 | +2,024 | 20,994 | +11% | $14K | ||
| Aug 17, 202617:57 | Aug 13, 2026 | RYTM | Chief Scientific Officer | S · Sell10b5-1 | $117.57 | −7,763 | 2,295 | -77% | −$913K | ||
| Aug 14, 202619:04 | Aug 13, 2026 | RYTM | EVP, Head of North America | S · Sell10b5-1 | $117.38 | −75,834 | 0 | -100% | −$8.9M | ||
| Aug 14, 202619:04 | Aug 13, 2026 | RYTM | EVP, Head of North America | M · Exercise10b5-1 | $17.62 | +56,601 | 75,834 | +294% | $997K | ||
| Aug 14, 202619:01 | Aug 12, 2026 | RYTM | EVP, Head of International | S · Sell10b5-1 | $116.15 | −57,000 | 55,655 | -51% | −$6.6M | ||
| Aug 14, 202619:01 | Aug 12, 2026 | RYTM | EVP, Head of International | M · Exercise10b5-1 | $6.80 | +46,625 | 112,655 | +71% | $317K |